Artykuły - Wybrane zagadnienia immunomodulacyjnego leczenia chorych na stwardnienie rozsiane
 
 
Zaloguj się...
Nazwa użytkownika:

Hasło użytkownika:

Zapamiętaj mnie



Zapomniałem hasła

Zarejestruj się!
Menu
Stowarzyszenie
Strona główna
Artykuły
Galeria
Forum
Download
Linki
 
Wybrane zagadnienia immunomodulacyjnego leczenia chorych na stwardnienie rozsiane
  Napisany Mon 21 Jan 2008 przez Cypek (5768 odsłon)

Piśmiennictwo
1. IFNB MSSG and the Univ. of Brit. Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
2. Johnson K. i wsp. and the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in RR MS: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
3. OWIMS. Evidence of interferon b-1a dose response in RR MS. Neurology 1999; 53: 679-686.
4. Goodin D., Frohman E., Garmany G. i wsp. Disease modifying therapies in multiple sclerosis. Neurology 2002; 58: 169-178.
5. Johnson K., Brooks B., Ford C. i wsp. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis 2000; 6: 255-256.
6. PRISMS-4. Long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
7. Jeffery D., Durden D., Burdette J. Trial of combined mitoxantrone and interferon beta-1b therapy in patients with worsened MS using monthly gadolinium enhanced MRI. Multiple Sclerosis 2001; 7: suppl. 1, S66.
8. Le Page E., Leray E., Coustans M. i wsp. Induction treatment with mitoxantrone during 6 months in worsening RR MS: a rescue therapy for sub-optimal responders to interferon beta? A pilot study. Multiple Sclerosis 2002; 8, suppl. 1, S126.
9. Mikol D. Treat early, but treat hard: interferon-b dose makes a difference. J Neuro-Opht 2001; 21: 237-239.
10. Coyle P., Hartung H.-P. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose – and frequency-dependent effects on clinical response. Multiple Sclerosis 2002; 8: 2-9.
11. Wroe S. Effects of interferon beta-1b titration on efficacy and tolerability. Multiple Sclerosis 2002; 8: suppl. 1, S118.
12. Durelli L. Dose and frequency of interferon treatment matter – INCOMIN and OPTIMS. The Schering Satellite Symposium at the 12th ENS Meeting. Berlin 2002, 8.
13. Johnson K., Brooks B., Ford C. i wsp. Results of the long-term (8-year) prospective, open label-trial of glatiramer acetate for relapsing multiple sclerosis. J Neurol 2002; 249: suppl. 1, I/204.
14. Cendrowski W. Convergence of relapse rates in Betaferon and placebo treated multiple sclerosis patients: indication for combination therapy? J Neurol Sci 2001; 187: suppl. 1, S452.
15. PRISMS Study Group. MRI results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of IFN-b1a in RR MS. Ann Neurol 1999; 46: 197-206.
16. Wolinsky J., Naravana P., Johnson K. i wsp. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis 2001; 7: 33-41.
17. Rice G., Kirk S., Nicolle E. i wsp. Further evidence for very long term efficacy in interferon beta-1b in relapsing remitting patients. Abstracts of the Benzon Symposium on Multiple Sclerosis. Copenhagen 2002, VI-6.
18. Cohen J., Goodman A., Heidenreich F. i wsp. Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive MS. Neurology 2001; 56: suppl. 3, A148-A149.
19. European Study Group on Interferon b-1b in Secondary Progressive MS. placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive MS. Lancet 1998; 352: 1491-1497.
20. Goodkin D. and NASPMS Study Group on Interferon beta-1b in secondary progressive MS. Clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54: 2352.
21. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001; 56: 1496-1504.
22. Kappos L., Polman C., Pozzilli C. i wsp. Final analysis of the European multicenter trial of IFN b-1b in secondary-progressive MS. Neurology 2001; 57: 1969-1975.
23. Brex P., Molyneux P., Smiddy P. i wsp. The effect of IFN b-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57: 2185-2190.
24. Cendrowski W. Przebieg naturalny i rokowania. W: Cendrowski W. Stwardnienie rozsiane. Wyd. 2. PZWL Warszawa 1993, 194-209.
25. Cendrowski W. The risk of treatment failure in secondary progressive multiple sclerosis: a short meta-analysis. Abstracts of the Benzon Symposium on Multiple Sclerosis. Copenhagen 2002, VI-2.
26. Proceedings of the Symposium on the importance of sustained efficacy in the treatment of multiple sclerosis. Adis International. Malaga 2002, 33-41.
27. Rudick R., Cutter G., Baier M. i wsp. Gadolinium enhancing lesions as a surrogate marker of interferon response. Multiple Sclerosis 2002; 8: suppl. 1, S21.
28. Kita M., Goodkin D. Treatment for progressive forms of MS. W: Hawkins C., Wolinsky J. (red.). Principles of Treatments in Multiple Sclerosis. Butterworth Heinemann. Oxford 2000, 148-162.
29. Casoni F., Manneschi L., Pesci I. i wsp. Multiple sclerosis: the question of unresponsiveness to interferon beta therapy. J Neurol 2002; 249: suppl. 1, I/202.
30. Khan O., Zvartau-Hind M., Caon Ch. i wsp. Effect of monthly intravenous cyclohosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Multiple Sclerosis 2001; 7: 185-188.
31. Barbero P., Pipieri A., Verdun E. i wsp. Is it possible to reduce the dose of interferon beta in MS patients with a prolonged MRI-confirmed absence of disease activity? AAN 54th Annual Meeting. Neurology 2002; 58, suppl. 3, A493.
32. Csepany T., Csiba L. Importance of continuous immunomodulatory treatment in multiple sclerosis. Multiple Sclerosis 2002; 8: suppl. 1, S123.
33. Beck R., Chandler D., Cole S. i wsp. Interferon b-1a for early MS: CHAMPS trial subgroup analysis. Ann Neurol 2002; 51: 481-490.
34. Rio J., Nos C., Borras C. i wsp. Transient and permanent treatment failure in a cohort of RRMS patients treated with interferon beta. Multiple Sclerosis 2001; 7: suppl. 1, S11.
35. Roullet E. Predictive value of the one-year clinical response to beta-interferon in relapsing-remitting multiple sclerosis. Multiple Sclerosis 2002; 8: suppl. 1, S82.
36. Tremlett H., Oger J. Non-adherence to the beta-interferons for multiple sclerosis in clinical practice. Multiple Sclerosis 2002; 8: suppl. 1, S35.
37. Mikol D., Burns T., Bennett S. i wsp. Patterns of MS treatment with disease modifying therapies before entry into an open label clinical trial of Rebif® injections. Multiple Sclerosis 2002; 8: suppl. 1, S88.
strona 2 z 2 poprzedni :: następny
Powrót :: Drukuj :: E-mail
 
Komentarze są własnością ich autorów. Nie ponosimy odpowiedzialności za ich treść.
Szukaj
Najnowsze artykuły
Najpopularniejsze artykuły
Kto jest online?
1 użytkowników jest na stronie (1 użytkowników przegląda Artykuły )

Użytkownicy: 0
Goście: 1

więcej...
Licznik

Copyright © by Biegusy 2006-2010
Stowarzyszenie Chorych na Stwardnienie Rozsiane SM w Zielonej Górze
Stwardnienie Rozsiane | Antymail | Forum stwardnienie rozsiane SM